西达基奥仑赛治疗后免疫效应细胞相关小肠结肠炎的诊断与管理
该研究回顾性分析梅奥诊所229例接受西达基奥仑赛(cilta-cel)治疗的患者,其中9例(3.9%)发生免疫效应细胞相关小肠结肠炎(IEC-EC),表现为持续性3级腹泻,常需长期全肠外营养。中位起病时间为输注后85天,糖皮质激素等一线治疗反应差,生物制剂使5例中3例获持久缓解。
要点
- cilta-cel后IEC-EC发生率为3.9%,表现为非血性3级腹泻,常伴胃肠道合并感染。
- 起病中位时间85天,独立相关因素包括高危疾病、迁延性CRS和既往迟发性神经毒性。
- 一线糖皮质激素等治疗反应差,生物制剂(维得利珠单抗/英夫利西单抗)可诱导持久缓解。
核心结论
- cilta-cel后IEC-EC罕见但预后差,早期内镜诊断和短期糖皮质激素失败后启用生物制剂可能改善结局。
研究设计与样本
- 回顾性队列研究,纳入梅奥诊所连续229例接受cilta-cel治疗的患者,其中9例(3.9%)发生IEC-EC。
主要发现
- 9例患者表现为非缓解性、非血性3级腹泻,常需长期全肠外营养,多数存在胃肠道合并感染。
- 从CAR-T输注至症状发作的中位时间为85天(范围35-166天),症状发作至内镜评估存在延迟。
- 十二指肠活检多显示类似移植物抗宿主病的黏膜损伤模式,2例呈T细胞淋巴增殖性疾病样模式(1例CD4+,1例CD8+)。
- 独立相关因素包括国际骨髓瘤学会和国际骨髓瘤工作组定义的高危疾病、迁延性细胞因子释放综合征和既往迟发性神经毒性。
关键数值与推荐
- 一线治疗(静脉或口服糖皮质激素、胆汁酸螯合剂、静脉免疫球蛋白及抗微生物治疗)反应差,无持久缓解。
- 生物制剂使5例中3例获持久缓解(维得利珠单抗2/2,英夫利西单抗1/3),缓解者均无胃肠道合并感染。
临床怎么用
- 对cilta-cel后出现持续性腹泻的患者,应早期请消化科会诊行内镜评估并包含十二指肠活检。
- 短期糖皮质激素治疗失败后,应考虑尽早启用生物制剂治疗。
局限性
- 回顾性研究,样本量小(9例),结论需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune effector cell-associated enterocolitis (IEC-EC) has been observed after ciltacabtagene autoleucel (cilta-cel [Carvykti]) chimeric antigen receptor T-cell (CAR-T) therapy. It is associated with dismal outcomes and is poorly characterized. Here, we examined its clinical features, risk factors, and proposed management strategies. Among the 229 consecutive patients who received cilta-cel at Mayo Clinic, 9 (3.9%) presented with a nonresolving, nonbloody, grade 3 diarrhea, often requiring prolonged total parenteral nutrition. Gastrointestinal coinfections were seen in most patients. Median time from CAR-T infusion to symptom onset was 85 days (range, 35-166), and there appeared to be a latency from symptom onset to endoscopic evaluation. Histopathology findings resembling a graft-versus-host disease pattern of mucosal injury were most seen on duodenal biopsies, whereas 2 cases had patterns akin to a T-cell lymphoproliferative disorder (1 CD4+ and 1 CD8+). Independent associated factors for IEC-EC included high-risk disease as defined by the International Myeloma Society and International Myeloma Working Group, prolonged cytokine release syndrome, and antecedent delayed neurotoxicity. Response to first-line therapy comprising IV or oral corticosteroids, bile acid sequestrants, IV immunoglobulin, and antimicrobial-directed therapy was poor, with no durable responses. Biologic therapy appeared to induce durable responses in 3 of the 5 patients (2/2 vedolizumab; 1/3 infliximab); none of the responders had gastrointestinal coinfection. Early gastroenterology input for endoscopic evaluation with the inclusion of duodenal biopsy is a key component for diagnosis. Early institution of biologic therapy after failure of a short course of corticosteroids should be considered.
引用
- Lim KJC, Lee HE, Chen ZE, et al. Diagnosis and management of immune effector cell-associated enterocolitis after ciltacabtagene autoleucel. Blood Adv. 2026. PMID: 41961998. doi:10.1182/bloodadvances.2025018853
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。